Sandra Collette

13.5k total citations · 7 hit papers
73 papers, 6.4k citations indexed

About

Sandra Collette is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Sandra Collette has authored 73 papers receiving a total of 6.4k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Surgery, 29 papers in Pulmonary and Respiratory Medicine and 28 papers in Oncology. Recurrent topics in Sandra Collette's work include Bladder and Urothelial Cancer Treatments (22 papers), Urinary and Genital Oncology Studies (15 papers) and Glioma Diagnosis and Treatment (11 papers). Sandra Collette is often cited by papers focused on Bladder and Urothelial Cancer Treatments (22 papers), Urinary and Genital Oncology Studies (15 papers) and Glioma Diagnosis and Treatment (11 papers). Sandra Collette collaborates with scholars based in Belgium, Netherlands and Germany. Sandra Collette's co-authors include Sandrine Marréaud, Richard Sylvester, Laurence Collette, Martin Köcher, S. Villà, Riccardo Soffietti, Brigitta G. Baumert, Rolf‐Peter Mueller, Tzahala Tzuk-Shina and Egils Valeinis and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

Sandra Collette

73 papers receiving 6.3k citations

Hit Papers

Adjuvant Whole-Brain Radiotherapy Versus Observation Afte... 2010 2026 2015 2020 2010 2010 2011 2015 2012 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study
    2010 1.4k citations Martin Köcher, Riccardo Soffietti et al. Journal of Clinical Oncology profile →
  2. A Prospective, Randomised EORTC Intergroup Phase 3 Study Comparing the Oncologic Outcome of Elective Nephron-Sparing Surgery and Radical Nephrectomy for Low-Stage Renal Cell Carcinoma
    2010 698 citations Sandrine Marréaud, Sandra Collette et al. European Urology profile →
  3. Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986
    2011 523 citations Maria De Santis, Joaquim Bellmunt et al. Journal of Clinical Oncology profile →
  4. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non–Muscle-invasive Stage Ta–T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-Guérin
    2015 444 citations Richard Sylvester, Laurence Collette et al. European Urology profile →
  5. Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guérin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance
    2012 340 citations Jorg R. Oddens, Maurizio Brausi et al. European Urology profile →
  6. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib
    2018 306 citations Sandrine Marréaud, Sandra Collette et al. profile →
  7. Phase 3 Trials of Stereotactic Radiosurgery With or Without Whole-Brain Radiation Therapy for 1 to 4 Brain Metastases: Individual Patient Data Meta-Analysis
    2015 295 citations Martin Köcher, Sandra Collette et al. International Journal of Radiation Oncology*Biology*Physics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sandra Collette Belgium 28 3.4k 2.6k 2.4k 1.3k 1.2k 73 6.4k
Christopher U. Jones United States 28 5.2k 1.5× 3.3k 1.3× 3.7k 1.6× 1.5k 1.2× 856 0.7× 68 10.3k
Juergen Dunst Germany 33 1.5k 0.4× 1.5k 0.6× 1.2k 0.5× 410 0.3× 464 0.4× 118 4.0k
Jürgen Dunst Germany 45 3.0k 0.9× 2.4k 0.9× 1.8k 0.7× 770 0.6× 217 0.2× 234 6.9k
Lance C. Pagliaro United States 41 2.4k 0.7× 2.1k 0.8× 2.1k 0.9× 1.6k 1.2× 193 0.2× 199 5.9k
Nevin Murray Canada 38 3.3k 1.0× 932 0.4× 3.3k 1.4× 1.4k 1.1× 123 0.1× 121 6.2k
Peter Wersäll Sweden 25 1.4k 0.4× 1.8k 0.7× 1.2k 0.5× 684 0.5× 153 0.1× 68 3.7k
Michael G. Haddock United States 50 4.1k 1.2× 5.3k 2.0× 4.1k 1.7× 291 0.2× 441 0.4× 260 8.9k
Howard Safran United States 47 3.9k 1.1× 2.7k 1.0× 5.7k 2.4× 1.4k 1.1× 314 0.3× 229 9.2k
Richard Fisher Australia 37 1.8k 0.5× 2.0k 0.8× 2.5k 1.1× 884 0.7× 129 0.1× 112 6.2k
Saul E. Rivkin United States 40 2.0k 0.6× 971 0.4× 3.6k 1.5× 820 0.6× 336 0.3× 127 5.8k

Countries citing papers authored by Sandra Collette

Since Specialization
Citations

This map shows the geographic impact of Sandra Collette's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandra Collette with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandra Collette more than expected).

Fields of papers citing papers by Sandra Collette

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandra Collette. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandra Collette. The network helps show where Sandra Collette may publish in the future.

Co-authorship network of co-authors of Sandra Collette

This figure shows the co-authorship network connecting the top 25 collaborators of Sandra Collette. A scholar is included among the top collaborators of Sandra Collette based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandra Collette. Sandra Collette is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Galsky, Matthew D., Dean F. Bajorin, J. Alfred Witjes, et al.. (2023). Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score. European Urology. 83(5). 432–440. 14 indexed citations
2.
Shankar, Lalitha, Erich P. Huang, Saskia Litière, et al.. (2022). Meta-Analysis of the Test–Retest Repeatability of [18F]-Fluorodeoxyglucose Standardized Uptake Values: Implications for Assessment of Tumor Response. Clinical Cancer Research. 29(1). 143–153. 3 indexed citations
3.
Bajorin, Dean F., J. Alfred Witjes, Jürgen E. Gschwend, et al.. (2021). First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC).. Journal of Clinical Oncology. 39(6_suppl). 391–391. 30 indexed citations
4.
Galsky, Matthew D., Abdel Saci, Péter M. Szabó, et al.. (2020). Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275. Clinical Cancer Research. 26(19). 5120–5128. 83 indexed citations
5.
Smits, Marion, Martin Bendszus, Sandra Collette, et al.. (2019). Repeatability and reproducibility of relative cerebral blood volume measurement of recurrent glioma in a multicentre trial setting. European Journal of Cancer. 114. 89–96. 19 indexed citations
6.
Οhyama, Chikara, Takahiro Kojima, Tsunenori Kondo, et al.. (2019). Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analyses. International Journal of Clinical Oncology. 24(9). 1089–1098. 18 indexed citations
7.
8.
9.
10.
Schöffski, Patrick, Agnieszka Woźniak, Bernard Escudier, et al.. (2017). Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial. European Journal of Cancer. 87. 147–163. 94 indexed citations
11.
Churilla, T.M., Elizabeth A. Handorf, Riccardo Soffietti, et al.. (2016). Does Whole-Brain Radiation Therapy for Oligometastatic Brain Metastases Translate Into a Survival Benefit for Patients With a Limited Competing Risk From Extracranial Disease? A Secondary Analysis of EORTC 22952-26001. International Journal of Radiation Oncology*Biology*Physics. 96(2). S56–S57. 1 indexed citations
12.
13.
Straube, William L., Coen Hurkmans, Christos Melidis, et al.. (2013). Quality assurance of radiotherapy in the ongoing EORTC 22042–26042 trial for atypical and malignant meningioma: results from the dummy runs and prospective individual case Reviews. Radiation Oncology. 8(1). 23–23. 19 indexed citations
14.
Daugaard, Gedske, Lisa Sengeløv, Mads Agerbæk, et al.. (2013). Phase I results from a study of lapatinib with gemcitabine and cisplatin (GC) in advanced/metastatic bladder cancer.. Journal of Clinical Oncology. 31(6_suppl). 252–252. 8 indexed citations
15.
Collette, Sandra, Richard Sylvester, Joaquim Bellmunt, et al.. (2013). Prognostics factors in previously untreated urothelial cancer patients ineligible for cisplatin-based chemotherapy: An external validation of the Bajorin risk groups.. Journal of Clinical Oncology. 31(15_suppl). 4529–4529. 1 indexed citations
16.
17.
Santis, Maria De, Joaquim Bellmunt, Graham M. Mead, et al.. (2011). Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986. Journal of Clinical Oncology. 30(2). 191–199. 523 indexed citations breakdown →
18.
Köcher, Martin, Riccardo Soffietti, Ufuk Abacıoğlu, et al.. (2010). Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study. Journal of Clinical Oncology. 29(2). 134–141. 1395 indexed citations breakdown →
19.
Collette, Sandra, Laurence Collette, Tom Budiharto, et al.. (2008). Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer – A study based on the EORTC trial 22881–10882 ‘boost versus no boost’. European Journal of Cancer. 44(17). 2587–2599. 157 indexed citations
20.
Collette, Sandra, Franck Bonnetain, Xavier Paolettí, et al.. (2008). Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials. Annals of Oncology. 19(6). 1117–1126. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christopher U. Jones Breakdown of academic impact, for papers by Juergen Dunst Breakdown of academic impact, for papers by Jürgen Dunst Breakdown of academic impact, for papers by Lance C. Pagliaro Breakdown of academic impact, for papers by Nevin Murray Breakdown of academic impact, for papers by Peter Wersäll Breakdown of academic impact, for papers by Michael G. Haddock Breakdown of academic impact, for papers by Howard Safran Breakdown of academic impact, for papers by Richard Fisher Breakdown of academic impact, for papers by Saul E. Rivkin
Rankless by CCL
2026